ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc., an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on March 11, 2019. The filing serves to announce the company's financial results for the quarter and full year ended December 31, 2018, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of results for the period ended December 31, 2018.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to obtain specific financial figures for the quarter and year ended December 31, 2018.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the exact date of the press release issuance (March 11, 2019) against the filing date.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.